S0916, MLN1202 in Treating Patients With Bone Metastases

Completed · Phase 2

Conditions studied: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Monoclonal antibodies, such MLN1202, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well MLN1202 works in treating patients with bone metastases.

Key facts

Study ID
NCT01015560
Run by
SWOG Cancer Research Network
People needed
44
Starts
2010-03-01
Expected to finish
2012-12-01
Last updated by the study team
2018-08-09

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.